Screener
Maze Therapeutics MAZE CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Investing activities | ||
| Purchases of marketable securities | (186,031) | — |
| Maturities of marketable securities | 64,000 | — |
| Purchases of property and equipment | (200) | (692) |
| Net cash used in investing activities | (122,231) | (692) |
| Financing activities | ||
| Proceeds from underwritten registered offering, net | 145,659 | — |
| Payment of underwritten registered offering costs | (1,090) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's capex?
- Maze Therapeutics (MAZE) reported capex of $107K in Q2 2026.
- How has Maze Therapeutics's capex changed year-over-year?
- Maze Therapeutics's capex decreased by 72.8% year-over-year, from $393K to $107K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Maze Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude